Medpace Holdings, Inc. filings document formal disclosures for a global clinical contract research organization, including 8-K reports that furnish quarterly and annual financial results. Those reports cover operating measures such as revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios for its Phase I-IV clinical development services.
Medpace filings also include proxy materials addressing governance, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document credit-facility amendments involving operating subsidiaries and executive-officer succession matters.
Medpace Holdings, Inc. (MEDP) director Cornelius P. McCarthy III converted 28 restricted stock units into 28 shares of common stock on September 30, 2026. His directly held common-stock position following the transaction was 12,303 shares.
Medpace Holdings, Inc. (MEDP) director Robert O. Kraft converted 32 restricted stock units into 32 shares of common stock on September 30, 2026. He held 987 common shares directly after the transaction. The units were part of a 130-unit award granted November 28, 2025, scheduled to vest in four approximately equal installments, including one on September 30, 2026.
Medpace Holdings, Inc. director Brian T. Carley converted 36 restricted stock units into 36 shares of common stock on September 30, 2026. After the transaction, he directly held 27,861 common shares and 35 restricted stock units. Each unit represents a contingent right to receive one share of MEDP common stock.
Medpace Holdings, Inc. President & CEO August J. Troendle reported direct sales of 26,701 common shares on September 29, 2026, at a weighted average of $621.02 per share, and 21,966 shares on September 30, 2026, at a weighted average of $625.47 per share. Both sales were effected through a limit order placed during an open window period; no Rule 10b5-1 plan is reported. A separate entry lists 4,733,019 shares held indirectly by Medpace Investors, LLC as of September 29, 2026. Troendle reported sole voting and investment control over those shares and disclaimed beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported direct sales of 2,410 common shares on September 28, 2026, at a weighted average price of $620.07 per share, and 154 shares on September 25, 2026, at $620.60 per share. A separate holding lists 4,733,019 shares held indirectly by Medpace Investors, LLC. Troendle is its sole manager and controlling unit holder, has sole voting and investment control, and disclaims beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) common stock was sold by reporting person August J. Troendle in open-market transactions pursuant to limit orders from August 10 through September 25, 2026. Troendle reported beneficial ownership of 5,396,508 shares (19.1%); Medpace Investors, LLC separately reported 4,733,019 shares (16.8%). Individual entries include a September 22, 2026, sale of 13,059 shares at a weighted-average price of $630.36 per share.
Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported direct sales of 16,083 shares at a weighted average price of $628.64 on September 23, 2026, and 27,833 shares at a weighted average price of $621.33 on September 24, 2026. The sales were made through a limit order during an open window period; no Rule 10b5-1 plan is reported. Separately, a holding entry dated September 23, 2026 lists 4,733,019 shares held indirectly by Medpace Investors, LLC. Troendle has sole voting and investment control over those securities and disclaims beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) President & CEO, director and ten percent owner August J. Troendle sold 21,883 common shares on September 21, 2026, at a weighted average price of $623.2900 per share, and 49,018 shares on September 22, 2026, at a weighted average price of $628.1100 per share. The reported price ranges were $620.00 to $625.91 and $620.00 to $632.815, respectively. Both sales were made pursuant to a limit order placed during an open window period, and no Rule 10b5-1 plan is reported. Separately, Medpace Investors, LLC held 4,733,019 shares as of September 21, 2026. Troendle is the LLC’s sole manager and controlling unit holder, has sole voting and investment control, and disclaims beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) reported that President & CEO and ten percent owner August J. Troendle sold 10,880 shares of Common Stock on September 17, 2026 in an open-market sale at a weighted average price of $620.40 per share, effected pursuant to a limit order during an open window period.
After this transaction, Troendle directly held 504,273 shares of Medpace common stock and also had indirect ownership of 4,733,019 shares held by Medpace Investors, LLC, over which he has sole voting and investment control while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported open-market sales of Medpace common stock. On September 15, 2026, he sold 15,971 shares at a weighted average price of $620.84, and on September 16, 2026, he sold 8,770 shares at a weighted average price of $621.29, for total reported sales of 24,741 shares.
The trades were effected pursuant to a limit order during an open window period. Troendle also reports 4,733,019 shares of Medpace common stock held indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unitholder; he may be deemed to beneficially own those securities but disclaims beneficial ownership except to the extent of his pecuniary interest.